Gilead Sciences Correlations
GILD Stock | USD 108.22 0.58 0.53% |
The current 90-days correlation between Gilead Sciences and Caribou Biosciences is 0.39 (i.e., Weak diversification). The correlation of Gilead Sciences is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Gilead Sciences Correlation With Market
Very weak diversification
The correlation between Gilead Sciences and DJI is 0.5 (i.e., Very weak diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Gilead Sciences and DJI in the same portfolio, assuming nothing else is changed.
Moving together with Gilead Stock
0.74 | PFE | Pfizer Inc | PairCorr |
0.81 | CGEN | Compugen | PairCorr |
0.68 | FNMFO | Federal National Mortgage | PairCorr |
0.71 | KB | KB Financial Group Earnings Call This Week | PairCorr |
0.74 | SHG | Shinhan Financial Earnings Call This Week | PairCorr |
0.7 | WF | Woori Financial Group Earnings Call This Week | PairCorr |
0.69 | CSCO | Cisco Systems | PairCorr |
0.65 | IBM | International Business Earnings Call This Week | PairCorr |
0.61 | AA | Alcoa Corp | PairCorr |
0.62 | CVX | Chevron Corp | PairCorr |
Related Correlations Analysis
0.92 | 0.82 | 0.43 | 0.85 | 0.97 | CRBU | ||
0.92 | 0.88 | 0.61 | 0.95 | 0.94 | CRSP | ||
0.82 | 0.88 | 0.4 | 0.84 | 0.81 | VERV | ||
0.43 | 0.61 | 0.4 | 0.7 | 0.51 | BEAM | ||
0.85 | 0.95 | 0.84 | 0.7 | 0.9 | PRME | ||
0.97 | 0.94 | 0.81 | 0.51 | 0.9 | SANA | ||
Click cells to compare fundamentals | Check Volatility | Backtest Portfolio |
Risk-Adjusted Indicators
There is a big difference between Gilead Stock performing well and Gilead Sciences Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Gilead Sciences' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
---|---|---|---|---|---|---|---|---|---|---|
CRBU | 5.41 | 1.36 | 0.24 | 0.77 | 4.79 | 12.02 | 23.18 | |||
CRSP | 2.85 | 0.66 | 0.22 | 0.56 | 2.83 | 7.09 | 16.14 | |||
VERV | 5.61 | 2.50 | 0.50 | (1.79) | 3.28 | 9.83 | 83.78 | |||
BEAM | 2.87 | 0.18 | 0.05 | 0.24 | 4.23 | 6.28 | 26.62 | |||
PRME | 6.84 | 1.82 | 0.30 | 1.04 | 5.67 | 21.58 | 41.91 | |||
SANA | 4.85 | 1.42 | 0.36 | 1.02 | 3.47 | 12.50 | 31.62 |
Gilead Sciences Corporate Management
Mr MD | VP Development | Profile | |
SeeChun MD | VP Oncology | Profile | |
Monica Tijerina | Clinical Manufacturing | Profile | |
Janet Dorling | Senior Solutions | Profile | |
Johanna Mercier | Chief Commercial Officer | Profile | |
Bilal Piperdi | Vice Oncology | Profile |